Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011. It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need.

Algiax’ lead compound AP-325, is a small molecule GABAA receptor modulator, which is in clinical development as a therapy for neuropathic pain. Algiax is currently testing AP-325 in a multicentre Phase 2 study in patients with chronic neuropathic pain after peripheral nerve injury.

Additionally, Algiax has discovered and characterized novel GABAA receptor modulator compounds called Thioacrylamide (ThAc) derivatives.

Through the cooperation between Algiax Pharmaceuticals GmbH and KomIT, a selection of the patented ThAc-derivatives was provided to the newly founded KomIT platform, whose main focus will be the treatment of diabetes. In addition to the ThAc derivatives, Algiax will contribute its many years of experience in preclinical and clinical drug development as well as its expertise in the preparation of regulatory documents and in the development of a regulatory strategy for a potential new drug.

Algiax’ strategy is to develop its drug candidates up to a Clinical Phase II-III stage and out-license them to pharmaceutical and biotech companies for further clinical development and market authorization.

For additional information, please visit